35.1 Acute Flares of Inflammatory Bowel Disease

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

35.1 Acute Flares of Inflammatory Bowel Disease

Key Takeaways Explain This Topic AI

Ulcerative colitis (UC) causes continuous mucosal-submucosal inflammation beginning in the rectum and extending proximally without skip lesions, marked by crypt abscesses, pseudopolyps, and rectal bleeding; Crohn disease (CD) causes transmural inflammation that can affect any segment from mouth to anus (predominantly terminal ileum), featuring skip lesions, non-caseating granulomas, strictures, and fistulas.

Acute IBD flares are frequently precipitated by NSAID use, intercurrent gastrointestinal infections (specifically Clostridioides difficile and CMV in refractory flares), medication non-adherence, and smoking alterations (active smoking worsens CD but paradoxically protects against UC; smoking cessation commonly precipitates UC flares).

Fecal calprotectin and fecal lactoferrin are sensitive non-invasive neutrophilic biomarkers used to differentiate inflammatory bowel disease flares from non-inflammatory functional disorders (IBS) and to monitor mucosal healing; systemic ESR and CRP reflect acute-phase inflammatory activity.

Truelove and Witts criteria classify severe UC flares by ≥6 bloody bowel movements per day accompanied by at least one systemic toxicity parameter: oral temperature >37.8°C (>100.0°F), pulse rate >90 bpm, hemoglobin <10.5 g/dL, or ESR >30 mm/h; severe flares mandate immediate hospital admission, intravenous methylprednisolone, chemical venous thromboembolism prophylaxis, and early colorectal surgical consultation.

Toxic megacolon is diagnosed by radiographic non-obstructive colonic distension >6 cm (most prominent in the transverse colon) plus systemic toxicity; anticholinergic agents, opioids, and endoscopic colonoscopy are strictly contraindicated due to acute colonic perforation risk. Long-term colorectal cancer surveillance colonoscopy begins 8 years after symptom onset for extensive colitis (every 1-2 years), but must begin annually immediately upon diagnosis if primary sclerosing cholangitis (PSC) co-exists.

Last updated: September 2026

Epidemiology, Pathophysiology & Phenotypic Differentiation: UC vs. Crohn Disease

Inflammatory bowel disease (IBD) encompasses two primary chronic idiopathic inflammatory conditions of the gastrointestinal tract: Ulcerative Colitis (UC) and Crohn Disease (CD) . In the United States, IBD affects approximately 1.6 to 3.1 million individuals, with peak bimodal incidence occurring between 15 to 30 years of age and a secondary, smaller peak between 50 to 70 years. While both disorders result from an inappropriate immune response to commensal enteric microflora in genetically susceptible hosts, their anatomical distribution, depth of tissue injury, endoscopic findings, histopathology, and clinical course diverge fundamentally.

Clinical and Pathologic Comparison: UC vs. CD

Pathologic / Clinical Feature Ulcerative Colitis (UC) Crohn Disease (CD)

Depth of Inflammation Mucosal and submucosal only; does not extend into the muscularis propria (except in fulminant colitis or toxic megacolon) Transmural inflammation extending through all layers of the intestinal wall from mucosa to serosa

Anatomical Distribution Limited to the large intestine ( colon and rectum ); starts in the rectum and extends proximally in an uninterrupted, continuous manner Any segment of the GI tract from mouth to anus ; characterized by discontinuous " skip lesions " with intervening normal mucosa

Rectal Involvement Rectum is almost universally involved (>95%) ; rectal sparing is an exceptional red flag for Crohn's Rectum is frequently spared (up to 50%); perianal disease (fissures, fistulae, skin tags) occurs in >30%

Small Bowel Involvement None; "backwash ileitis" (mild, patchy, superficial erythema of distal 2-3 cm of terminal ileum) occurs in 10-20% of severe pancolitis Terminal ileum is involved in 70-80% of patients ("terminal ileitis"); isolated small bowel disease occurs in 30%

Gross Endoscopic Appearance Diffuse, uniform erythema, loss of normal vascular pattern, granular friable mucosa, superficial erosions, and inflammatory pseudopolyps (islands of regenerating mucosa) Aphthous ulcers progressing to deep, linear, knife-like ("serpiginous") ulcerations separated by edematous mucosa, creating a cobblestone appearance

Radiographic Features Barium enema reveals loss of haustral markings, mucosal granularity, and a smooth, rigid tubular appearance (" lead-pipe colon ") Fluoroscopic small bowel series or CT/MR enterography reveals luminal narrowing, wall thickening, " string sign " in terminal ileum, and strictures

Histopathology Crypt architectural distortion , mucosal atrophy, branched crypts, acute cryptitis, and neutrophilic crypt abscesses within epithelial crypt lumens; NO granulomas Transmural lymphoid aggregates, submucosal thickening, deep clefts, and pathognomonic non-caseating epithelioid granulomas (present in 50-60% of transmural biopsies)

Cardinal Symptoms Bloody diarrhea (hematochezia) , prominent rectal urgency, painful tenesmus , and frequent small-volume mucoid stools Crampy abdominal pain (especially right lower quadrant ), non-bloody or intermittently bloody diarrhea, systemic weight loss, fever, and malabsorption

Structural Complications Severe mucosal hemorrhage, acute colonic perforation, toxic megacolon , and high lifetime risk of colorectal adenocarcinoma Strictures causing mechanical bowel obstruction, fistulas (enteroenteric, enterocutaneous, enterovesical, rectovaginal), intra-abdominal abscesses, perianal disease

Extraintestinal Manifestations Strongly linked to Primary Sclerosing Cholangitis (PSC) (70-80% of PSC patients have UC), pyoderma gangrenosum, erythema nodosum, uveitis/episcleritis, peripheral arthropathy Gallstones (due to impaired ileal bile salt reabsorption), calcium oxalate nephrolithiasis (enteric hyperoxaluria from malabsorption), pyoderma gangrenosum, erythema nodosum, ankylosing spondylitis

Environmental Modifiers & Provocative Triggers of Acute Flares

IBD is characterized by unpredictable cycles of clinical remission punctuated by acute inflammatory flares. Identifying and rapidly correcting modifiable exogenous triggers is vital in primary care practice:

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) :

Both non-selective NSAIDs (ibuprofen, naproxen, ketorolac) and selective COX-2 inhibitors inhibit gastroprotective prostaglandin E2 (PGE2) synthesis within the colonic mucosa.

Loss of mucosal prostaglandins impairs mucosal microvascular blood flow, increases intestinal epithelial permeability, facilitates bacterial translocation, and precipitates acute clinical relapse in up to 20% to 30% of patients within 1 to 2 weeks of initiation.

Clinical Mandate : Acetaminophen (up to 2-3 g/day) should be utilized for analgesia and antipyresis; NSAIDs should be strictly avoided.

Superimposed Enteric Infections :

Clostridioides difficile Infection (CDI) : IBD patients have a 3- to 8-fold increased susceptibility to C. difficile , even in the absence of recent antibiotic exposure or hospitalization. CDI mimics an idiopathic flare, accelerates clinical deterioration, and quadruples mortality if unrecognized. Every patient presenting with an acute IBD flare must undergo stool testing for C. difficile GDH antigen and Toxin A/B EIA with reflex NAAT .

Cytomegalovirus (CMV) Colitis : CMV reactivation within granulation tissue is a frequent cause of acute flare refractory to intravenous corticosteroid therapy. In patients hospitalized with severe steroid-refractory colitis, flexible sigmoidoscopy with mucosal biopsy must evaluate for intranuclear inclusion bodies ("owl's eye" inclusions) and CMV immunohistochemistry; confirmed cases require intravenous ganciclovir (5 mg/kg IV every 12 hours).

Common bacterial pathogens ( Campylobacter , Salmonella , Shigella , E. coli O157:H7) must also be excluded via multiplex stool PCR or stool culture.

The Smoking Paradox :

Crohn Disease : Tobacco smoking is a potent deleterious modifier. Active cigarette smoking doubles the risk of developing CD, triples the rate of clinical flares, accelerates stricture and fistula formation, increases the need for immunosuppressive therapy, and significantly raises the rate of postoperative surgical recurrence. Complete smoking cessation is mandatory.

Ulcerative Colitis : Cigarette smoking displays an enigmatic, paradoxical protective association. Current smokers have a lower incidence of UC and a milder clinical course. Crucially, smoking cessation frequently precipitates severe, new-onset UC flares or triggers the initial clinical presentation within the first 1 to 3 years following tobacco discontinuation. Nicotine stimulates colonic mucin secretion and alters mucosal helper T-cell profiles; however, resumption of smoking is never recommended therapeutically due to cardiovascular and oncologic hazards.

Medication Non-Adherence & Underdosing :

Premature discontinuation of maintenance 5-aminosalicylate (5-ASA) or biologic therapy (due to cost, pill burden, or symptom resolution) is responsible for over 40% of outpatient flares.

In patients receiving biologic agents (e.g., infliximab, adalimumab), secondary loss of response commonly occurs due to the development of neutralizing anti-drug antibodies (ADAs) and subtherapeutic serum trough drug concentrations.

Biomarkers of Active Inflammation & Diagnostic Triage

Objective biomarkers are essential in ambulatory family medicine to distinguish active inflammatory flares from non-inflammatory functional gastrointestinal symptoms (e.g., overlapping irritable bowel syndrome, small intestinal bacterial overgrowth, or bile acid diarrhea) and to guide treatment intensification without requiring immediate invasive colonoscopy. OBJECTIVE BIOMARKER TRIAGE IN IBD

• Patient with Known IBD Presents with Diarrhea & Cramps
• │
• ┌──────────────────────┴──────────────────────┐
• ▼ ▼
• Systemic Inflammatory Fecal Neutrophilic
• Biomarkers Biomarkers
• CRP (>5-10 mg/L = active systemic) • Fecal Calprotectin (>150-250 mcg/g)
• ESR (>30 mm/h in severe UC) • Fecal Lactoferrin (elevated)
• CBC (anemia, thrombocytosis >450k) • Rules OUT functional symptoms (IBS)
• Albumin (<3.0 g/dL = severe disease) • High correlation with mucosal ulceration
• │ │
• └──────────────────────┬──────────────────────┘
• ▼
• Exclude Superimposed Infection
• Stool C. diff GDH / Toxin PCR
• Multiplex GI Pathogen NAAT
• │
• ▼
• Stratify Truelove & Witts Severity
• Mild/Moderate: Outpatient 5-ASA / Corticosteroids
• Severe: Urgent Hospital Admission & IV Steroids
• Non-Invasive Stool Biomarkers

Fecal Calprotectin : A 36-kDa calcium- and zinc-binding protein derived predominantly from the cytosol of degranulating mucosal neutrophils. It is extremely stable in stool at room temperature for up to 7 days.

Values <50 mcg/g : Highly sensitive (>95%) for the absence of significant mucosal inflammation; strongly points toward functional bowel symptoms (irritable bowel syndrome) rather than an active IBD flare.

Values 50 to 150 mcg/g : Borderline zone; represents low-grade inflammation or resolving flare.

Values >150 to 250 mcg/g : Highly specific (>85-90%) for active mucosal endoscopic inflammation, crypt abscesses, and mucosal ulceration. Serial measurements serve as a surrogate marker for endoscopic mucosal healing.

Fecal Lactoferrin : An iron-binding glycoprotein contained within the secondary granules of polymorphonuclear neutrophils. Reflects acute mucosal leukocyte infiltration and parallels calprotectin performance.

Systemic Serum Biomarkers

C-Reactive Protein (CRP) : Acute-phase reactant synthesized by hepatocytes under IL-6 stimulation. Rises briskly in active Crohn disease (which exhibits a strong transmural systemic cytokine surge), but may remain normal or only mildly elevated in up to 30% to 50% of patients with active, mild-to-moderate ulcerative colitis restricted to the rectum or left colon.

Erythrocyte Sedimentation Rate (ESR) : Reflects elevated fibrinogen; incorporated into the classic Truelove and Witts criteria for UC severity.

Complete Blood Count (CBC) :

Platelets : Thrombocytosis (>450,000/mcL) is a sensitive acute-phase marker reflecting active mucosal ulceration.

Hemoglobin/Hematocrit : Microcytic hypochromic anemia (chronic gastrointestinal blood loss and iron deficiency) combined with normocytic anemia of chronic disease.

Serum Albumin : Marked hypoalbuminemia (<3.0 g/dL) results from mucosal exudative protein loss ("protein-losing enteropathy") and cytokine-mediated suppression of hepatic synthesis; it serves as a powerful negative prognostic indicator predicting failure of medical therapy and heightened colectomy risk.

Truelove and Witts Criteria for Ulcerative Colitis Flare Severity

In ambulatory and urgent care settings, the validated Truelove and Witts criteria remain the clinical gold standard for risk-stratifying acute flares of ulcerative colitis and determining the immediate level of care:

Truelove and Witts Severity Classification Table

Severity Category Stool Frequency (per 24 hours) Macroscopic Blood in Stools Systemic Signs: Temperature Systemic Signs: Heart Rate Systemic Signs: Hemoglobin Systemic Signs: ESR / CRP

Mild <4 stools per day Absent, trace, or intermittent small streaks Afebrile (<37.5°C / 99.5°F) Normal (<90 bpm) Normal (>11.5 g/dL) Normal (<20 mm/h)

Moderate 4 to 6 stools per day Mild to moderate blood present Intermediate between mild and severe Intermediate (≤90 bpm) Mild reduction (10.5 to 11.5 g/dL) Mild elevation (20 to 30 mm/h)

Severe ≥6 bloody stools per day Continuous, frank macroscopic hematochezia Fever >37.8°C (100.0°F) on at least 2 of 4 days Tachycardia >90 bpm Severe anemia (<10.5 g/dL) ESR >30 mm/h (or serum CRP >30 mg/L)

Fulminant / Toxic >10 bloody stools per day Continuous, gross bleeding requiring transfusion High spiking fever (>38.5°C / 101.3°F) Marked tachycardia (>110-120 bpm) Profound anemia requiring urgent transfusion ESR >50 mm/h; Leukocytosis >12,000/mcL with left shift

Diagnostic Decision Rule : Severe colitis requires ≥6 bloody bowel movements daily PLUS at least ONE of the four systemic toxicity criteria (fever, tachycardia, anemia, or elevated ESR/CRP). The presence of fulminant colitis or localized peritonitis signals impending perforation or toxic megacolon and mandates emergency inpatient surgical and medical care.

Outpatient Medical Management of Mild-to-Moderate Flares

Outpatient management focuses on rapid induction of mucosal remission while transitioning or optimizing a maintenance therapeutic regimen.

1. Ulcerative Colitis: Topical & Oral 5-ASA Optimization

Ulcerative Proctitis (Disease limited to distal 15 cm from anal verge) :

First-Line Induction : Mesalamine rectal suppository 1,000 mg (1 g) once daily at bedtime .

Pharmacokinetic Pearl : Suppositories melt at body temperature and disperse active mesalamine directly into the rectal vault up to the rectosigmoid junction (15-20 cm). Clinical trial evidence proves topical rectal mesalamine is significantly superior to oral mesalamine and superior to topical rectal corticosteroids for proctitis.

Left-Sided Colitis (Disease extending from rectum to splenic flexure) :

First-Line Induction : Mesalamine rectal enema 4 g once daily at bedtime PLUS Oral Mesalamine 2.4 to 4.8 g per day .

Pharmacokinetic Pearl : Liquid enemas have a delivery volume of 60 mL, which readily refluxes retrogradely throughout the descending colon up to the splenic flexure. Combined topical and oral 5-ASA therapy yields significantly higher clinical and endoscopic remission rates than either agent alone.

Extensive Colitis / Pancolitis (Extending proximal to the splenic flexure) :

Oral Mesalamine 2.4 to 4.8 g once daily (or split dosing) combined with bedtime mesalamine enemas for rapid relief of distal tenesmus and rectal bleeding.

Alternative: Sulfasalazine 3 to 4 g/day in divided doses (requires concurrent oral folic acid 1 mg daily , as sulfasalazine competitively inhibits intestinal folate conjugate absorption).

2. Mild-to-Moderate Flares Refractory to 5-ASA: Oral Corticosteroid Induction

When patients fail to achieve clinical improvement on maximized 5-ASA within 2 to 4 weeks, or present with moderate flare severity:

Oral Budesonide MMX (Multi-Matrix System, 9 mg once daily in the morning for 8 weeks) :

Specially formulated for ulcerative colitis; releases budesonide throughout the entire colon. Exhibits >90% hepatic first-pass metabolism via cytochrome P450 3A4, delivering high local anti-inflammatory activity while minimizing systemic glucocorticoid toxicities.

Oral Controlled-Ileal-Release Budesonide (Entocort EC, 9 mg once daily for 8 weeks, followed by a 2-4 week taper) :

First-Line Induction for Mild-to-Moderate Ileocecal Crohn Disease (involving the terminal ileum and/or ascending colon).

Formulated with an enteric ethylcellulose coating that dissolves at pH >5.5 (ileocecal junction), achieving high target tissue concentrations with minimal systemic absorption.

Clinical Distinction : Controlled-release budesonide is ineffective for extensive colonic Crohn's or left-sided colitis because the drug is released exclusively in the ileum and right colon.

Oral Systemic Prednisone (40 to 60 mg orally once daily for 1 to 2 weeks, followed by a structured taper of 5-10 mg weekly over 8 to 12 weeks) :

Indicated for moderate-to-severe UC or CD flares that do not respond to topical therapy or budesonide.

Important

STRICT GUIDELINE RULE : Systemic corticosteroids are effective ONLY for acute induction of remission ; they are COMPLETELY INEFFECTIVE and STRICTLY CONTRAINDICATED for maintenance therapy due to failure to achieve mucosal healing, high relapse rates, and severe long-term morbidities (osteoporosis, avascular necrosis, cataracts, opportunistic infections, adrenal suppression, impaired wound healing).

Hospitalization Criteria & Inpatient Management of Severe / Fulminant Colitis

Any patient fulfilling Truelove and Witts severe or fulminant criteria, or demonstrating hemodynamic instability, peritoneal irritation, severe intractable dehydration, failure of outpatient oral corticosteroids after 5 to 7 days, or severe malnutrition, requires immediate hospital admission.

Standard Inpatient Severe Colitis Protocol

Intravenous Corticosteroid Therapy :

Methylprednisolone 60 mg IV once daily (or Hydrocortisone 100 mg IV every 8 hours ).

Doses higher than 60 mg/day of methylprednisolone provide no additional therapeutic benefit and dramatically increase adverse events.

Chemical Venous Thromboembolism (VTE) Prophylaxis :

Caution

CRITICAL EXAM PEARL: VTE PROPHYLAXIS IN ACTIVE IBD BLEEDING

Patients hospitalized with active IBD flares have a 3- to 8-fold increased risk of deep vein thrombosis (DVT) and fatal pulmonary embolism (PE) driven by cytokine-mediated hypercoagulability, thrombocytosis, and elevated fibrinogen.

Active rectal bleeding / hematochezia is NOT a contraindication to chemical VTE prophylaxis! All hospitalized IBD patients must receive prophylactic anticoagulation with low-molecular-weight heparin (enoxaparin 40 mg SQ daily) or low-dose unfractionated heparin (5,000 units SQ every 8-12 hours) , unless there is massive, hemodynamically destabilizing life-threatening hemorrhage.

Bowel Rest & Nutrition :

Bowel rest (NPO with IV isotonic fluids) is reserved for severe toxic patients or impending surgery. Enteral nutrition is preferred over total parenteral nutrition (TPN) whenever tolerated.

Early Surgical Consultation :

An experienced colorectal surgical team must be involved on Day 1 of admission to co-manage the patient and prepare for potential emergency subtotal colectomy.

Day 3 to Day 5 Decision Point: Oxford Criteria & Rescue Therapy :

Clinical response to IV steroids must be rigorously evaluated on Day 3 using the validated Oxford Criteria :

If on Day 3 of IV steroids, the patient has >8 bowel movements per day , OR 3 to 8 bowel movements per day with a serum CRP >45 mg/L , the risk of failing medical therapy and requiring emergent colectomy exceeds 85% .

Rescue Medical Therapy : Do not continue ineffective steroids indefinitely. Initiate rescue therapy with:

Infliximab (anti-TNF alpha) : 5 to 10 mg/kg IV infusion at weeks 0, 2, and 6 (often accelerated dosing for severe hypoalbuminemic colitis); OR

Cyclosporine IV : Continuous infusion of 2 mg/kg/day targeting whole blood trough levels of 150 to 250 ng/mL.

If the patient does not achieve clear, substantial clinical improvement within 48 to 72 hours of rescue therapy, emergency subtotal colectomy with end ileostomy is life-saving.

Toxic Megacolon: Pathophysiology, Clinical Criteria & Emergency Care

Toxic megacolon is a catastrophic, potentially lethal complication of severe colitis occurring in 1% to 5% of IBD patients (most frequently in ulcerative colitis, but also seen in Crohn's colitis, C. difficile pseudomembranous colitis, and ischemic colitis).

Pathophysiology

Inflammation extends through the submucosa into the circular and longitudinal smooth muscle layers of the muscularis propria ( transmural necrosis ). Degranulating neutrophils and macrophages release massive amounts of inflammatory cytokines and inducible nitric oxide synthase (iNOS). High concentrations of nitric oxide paralyze colonic smooth muscle myocytes, abolishing basal motor tone and peristalsis. The colonic lumen rapidly dilates with gas and liquid feces. The colonic wall thins to paper-thin caliber, predisposing to microperforation, gross transmural perforation, fecal peritonitis, and septic shock.

Diagnostic Criteria (Jalan / Truelove Criteria)

Diagnosis requires radiographic evidence of non-obstructive colonic dilation combined with systemic toxicity : DIAGNOSTIC CRITERIA FOR TOXIC MEGACOLON

• 1. Radiographic Criterion: Colonic distension >6 cm (most prominent in
• the transverse colon on supine abdominal radiograph / CT)
• +

2. At least THREE of the following systemic inflammatory features:

• Fever >38.6°C (101.5°F)
• Heart rate >120 beats per minute
• Leukocytosis >10,500 cells/mcL (or >10% immature band forms)
• Anemia (Hemoglobin <10.5 g/dL)
• +

3. At least ONE of the following clinical toxicity signs:

• Dehydration / hypovolemia
• Altered mental status / acute confusion
• Electrolyte disturbances (hypokalemia, hypomagnesemia)
• Systemic hypotension / septic shock
• Iatrogenic Precipitating Factors & Absolute Contraindications

Warning

STRICT SAFETY CONTRAINDICATIONS IN SEVERE COLITIS & MEGACOLON Toxic megacolon is frequently precipitated by medications or procedures that paralyze colonic motility or increase luminal wall tension:

Antimotility Agents & Opioids : Loperamide, diphenoxylate-atropine, morphine, oxycodone, and hydromorphone.

Anticholinergic Agents : Dicyclomine, hyoscyamine, oxybutynin, and tricyclic antidepressants.

Diagnostic Colonoscopy & Barium Enema : Full optical colonoscopy and contrast barium enemas are STRICTLY CONTRAINDICATED ! Mechanical air insufflation, colonoscope insertion, and barium hydrostatic pressure dramatically accelerate wall tension, triggering immediate colonic perforation and catastrophic fecal peritonitis. If mucosal evaluation is mandatory, perform only a gentle, unprepared flexible sigmoidoscopy with minimal air/CO2 insufflation.

Emergency Management Protocol

Immediate Medical Resuscitation :

Complete bowel rest (strict NPO).

Placement of a nasogastric (NG) tube for gastric decompression.

Aggressive intravenous isotonic crystalloid fluid resuscitation to restore intravascular volume.

Aggressive correction of electrolyte abnormalities (especially hypokalemia and hypomagnesemia , which directly impair colonic muscular contraction).

Frequent patient repositioning: The " roll-over maneuver " (turning the patient from supine to prone or knee-chest position for 15 minutes every 2 hours) allows buoyant gas trapped in the anterior transverse colon to migrate retrogradely into the rectum, facilitating decompression.

Pharmacotherapy :

Intravenous Methylprednisolone 60 mg daily .

Broad-Spectrum Intravenous Antibiotics : To cover enteric Gram-negative bacilli and anaerobes translocating across the compromised, necrotic colonic mucosa (e.g., Ceftriaxone 2 g IV daily PLUS Metronidazole 500 mg IV every 8 hours , or Piperacillin-Tazobactam 3.375-4.5 g IV every 6 hours ).

Serial Surveillance & Emergency Surgical Indications :

Serial abdominal plain radiographs (supine KUB) and physical examinations every 12 hours.

Immediate Emergency Surgery (Subtotal Colectomy with End Ileostomy) is indicated for:

• Free intra-abdominal air (perforation);
• Worsening localized or generalized peritonitis;
• Hemodynamic collapse / progressive septic shock; OR

Failure of maximal medical therapy to decrease colonic caliber within 24 to 72 hours.

Colorectal Cancer (CRC) Surveillance Protocols in IBD

Patients with long-standing inflammatory bowel disease involving the colon face a substantially elevated risk of developing colorectal adenocarcinoma. Unlike sporadic CRC, which arises via the traditional adenoma-to-carcinoma sequence (initiating with APC mutation and progressing to KRAS and p53 over 10-15 years), colitis-associated colorectal cancer arises via the chronic inflammation-dysplasia-carcinoma pathway . In this setting, loss of p53 occurs early in non-dysplastic or inflamed mucosa, leading to multifocal, flat, non-polypoid dysplastic lesions that are notoriously difficult to detect.

Colorectal Cancer Surveillance Guidelines Table

Clinical Phenotype / Risk Category Timing of Initial Screening Colonoscopy Recommended Surveillance Frequency High-Yield Clinical Considerations

Extensive Colitis / Pancolitis (UC or Crohn's colitis proximal to splenic flexure) 8 years after symptom onset (NOT 8 years after the formal date of diagnosis) Every 1 to 2 years based on risk stratification Risk is proportional to the duration and cumulative microscopic and macroscopic severity of mucosal inflammation.

Left-Sided Colitis (UC or Crohn's extending between rectum and splenic flexure) 8 to 12 years after symptom onset Every 1 to 2 years Proctosigmoiditis carries intermediate risk; modern guidelines align surveillance initiation at 8 years.

Ulcerative Proctitis Alone (Disease strictly limited to distal rectum <15 cm) General population screening age (Age 45) Routine general population intervals NO increased risk of CRC compared to the general population; specialized IBD surveillance protocols are not required.

Co-existing Primary Sclerosing Cholangitis (PSC) Immediately at the time of PSC diagnosis , regardless of IBD duration or disease activity Annually for life PSC-IBD confers a devastating 5- to 10-fold further increase in CRC risk and a high risk of cholangiocarcinoma; surveillance must begin on day 1 of PSC diagnosis.

High-Risk Post-Colonoscopy Features (Documented stricture, personal history of dysplasia, severe active inflammation) N/A Annually Requires referral to an expert inflammatory bowel disease endoscopic center.

Surveillance Modalities & Endoscopic Technique

High-Definition Chromoendoscopy : Involves spraying topical dye (indigo carmine or methylene blue) or using digital virtual chromoendoscopy (narrow-band imaging [NBI]) to highlight mucosal pit patterns and identify flat, subtle dysplastic lesions. Targeted biopsies are taken of all suspicious mucosal irregularities.

Standard White-Light Colonoscopy : If chromoendoscopy is unavailable, random 4-quadrant mucosal biopsies must be obtained every 10 cm throughout the entire colon, yielding a minimum of 32 to 33 biopsies to provide acceptable statistical sensitivity.

Management of Dysplasia :

Visible, circumscribed polypoid dysplasia : If the lesion can be completely resected endoscopically and surrounding mucosal biopsies are free of dysplasia, close endoscopic surveillance is acceptable.

Invisible dysplasia (detected on random biopsy) or multifocal high-grade dysplasia : Mandates total proctocolectomy with ileal pouch-anal anastomosis (IPAA) due to an exceptionally high risk of synchronous invasive adenocarcinoma (>40-50%).

Loading diagram... Clinical Triage and Management of Acute Inflammatory Bowel Disease Flares